We have been selected to evaluate an innovative therapy in this terrible disease. We will begin a Ib Phase clinical trial to evaluate the safety of an antiTau monoclonal antibody. If it is positive, we will participate in the development of the phase II trial to also check the efficacy and safety of different doses of this drug.
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
This study could improve the efficacy and safety of the products being evaluated to try…
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa,…
Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s,…
Our Unit has surpassed two centers from the United States in the randomization of patients…
On February 7, 2019, at the Exchange Conference UIC (Universitat Internacional de Catalunya) and the…
Our unit has received the congratulations of a patient, after finishing his participation in a…
Más idiomas
ES / EN / CAT son las versiones oficiales revisadas.
